Rare Hemophilia Factors Market by Method and Geography - Forecast and Analysis 2022-2026

The rare hemophilia factors market share is expected to increase to USD 146.76 million from 2021 to 2026, at a CAGR of 7.4%.

This rare hemophilia factors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers rare hemophilia factors market segmentation by method (fresh frozen plasma, factor concentrates, cryoprecipitate, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The rare hemophilia factors market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, and Intermountain Healthcare among others.

What will the Rare Hemophilia Factors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Rare Hemophilia Factors Market Size for the Forecast Period and Other Important Statistics

 

Rare Hemophilia Factors Market: Key Drivers, Trends, and Challenges

The approval of new treatment techniques is notably driving the rare hemophilia factors market growth, although factors such as cost-intensive and complex treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the rare hemophilia factors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Rare Hemophilia Factors Market Driver

One of the key factors driving the global rare hemophilia factors market growth is the approval of new treatment techniques. Patients with hemophilia have the option of choosing different effective and safe treatments, including novel extended half-life therapeutics that can overcome the current prophylaxis limitations, particularly in patients with hemophilia B. Among the different types of hemophilia, A and B are the most common. According to the CDC, every year, hemophilia A affects 1 in 5,000 male births, and approximately 400 babies are born with hemophilia A each year in the US. Therapies such as replacement therapy for hemophilia A and hemophilia B provide missing coagulation factors and have been the mainstay of treatment in hemophilic patients. Several players in the market are focused on identifying novel strategies to treat hemophilia. For instance, in February 2020, Novo Nordisk launched the US FDA-approved ESPEROCT to treat adults and children with hemophilia A. Such factors will drive market growth in the coming years. 

Key Rare Hemophilia Factors Market Trend

Advent of gene therapy is one of the key rare hemophilia factors market trends that is expected to impact the industry positively in the forecast period. The aim of gene therapy for hemophilia is to deliver stable insertion and expression of a gene, the absence of which is responsible for hemophilia A or B. Some examples of gene therapy development to treat hemophilia are listed below:

• In December 2021, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, investigational gene therapy for patients with moderately severe to severe hemophilia A.
• In May 2019, the company announced the submission of data from its Phase III clinical trial to regulators for approval. 

Key Rare Hemophilia Factors Market Challenge

One of the key challenges to the global rare hemophilia factors market growth is the cost-intensive and complex treatment. The current treatments pose certain limitations, such as the risk of infection, treatment resistance, poor compliance, and adverse effects. Recombinant therapies are associated with the development of inhibitors. It is estimated that approximately 30% of hemophilia A afflicted population undergoing therapy are susceptible to adverse immunogenic reactions. Plasma-based therapies are associated with the risk of transmission of blood-borne disorders such as HIV, hepatitis B, and hepatitis C. Though primary screening of blood is done, the risk of transmission of these infections during transfusion is high, due to the presence of different strains of pathogens. Such factors may impede market growth in the coming years.

This rare hemophilia factors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global rare hemophilia factors market as a part of the pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the rare hemophilia factors market during the forecast period.

Who are the Major Rare Hemophilia Factors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Alnylam Pharmaceuticals Inc.
• Aptevo Therapeutics Inc.
• Bayer AG
• Bio Products Laboratory Ltd.
• Catalyst Biosciences, Inc.
• CSL Ltd.
• F. Hoffmann La Roche Ltd.
• Genentech Inc.
• Grifols SA
• Kedrion Spa
• Novo Nordisk
• Octapharma AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• The Johns Hopkins Health System Corp.
• UCSF Health
• uniQure NV
• Versiti
• Intermountain Healthcare

 

This statistical study of the rare hemophilia factors market encompasses successful business strategies deployed by the key vendors. The rare hemophilia factors market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

• Bayer AG - The company offers rare hemophilia factors that provide substitution therapy which helps to protect you from joint bleeds and blood-borne viruses.
• Aptevo Therapeutics Inc. - The company offers rare hemophilia factors that include adapters technology, adaptir-flex technology that helps to protect from joint bleeds, and blood-borne viruses.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The rare hemophilia factors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Rare Hemophilia Factors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the rare hemophilia factors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Rare Hemophilia Factors Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for rare hemophilia factors in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The presence of key market players and a significant increase in investment in R&D will facilitate the rare hemophilia factors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Method Segments in the Rare Hemophilia Factors Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The rare hemophilia factors market share growth by the fresh frozen plasma segment will be significant during the forecast period. Fresh frozen plasma is used to treat bleeding associated with an increased PT (>1.5 times normal) or aPTT (>2 times normal). In an average-sized adult, one unit of fresh frozen plasma increases coagulation factors by around 3%. For coagulopathic bleeding, a dose of 10 to 15 ml/kg (typically about four units) is sufficient for initial treatment. FFP is used in the treatment of many severe to chronic illnesses, which will drive the segment growth in the coming years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the rare hemophilia factors market size and actionable market insights on post COVID-19 impact on each segment.

 

Rare Hemophilia Factors Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Decelerate at a CAGR of 7.4%
Market growth 2022-2026	$ 146.76 million
Market structure	Fragmented
YoY growth (%)	9.97
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key consumer countries	US, Canada, Germany, UK, and Japan
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, and Intermountain Healthcare
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Rare Hemophilia Factors Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive rare hemophilia factors market growth during the next five years
• Precise estimation of the rare hemophilia factors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the rare hemophilia factors industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of rare hemophilia factors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch